Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Liu, Xiang hua ^a   Sun, Ming ^a   Nie, Feng qi ^a   Ge, Ying bin ^a   Zhang, Er bao ^a   Yin, Dan dan ^a   Kong, Rong ^a   Xia, Rui ^a   Lu, Kai hua ^a   Li, Jin hai ^a   De, Wei ^a   Wang, Ke ming ^b   Wang, Zhao xia ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Competing endogenous RNA; Gastric cancer; HER2; HOTAIR; Proliferation and invasion

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HOX TRANSCRIPT ANTISENSE INTERGENIC RNA; LONG UNTRANSLATED RNA; MICRORNA; MICRORNA 331 3P; RNA BINDING PROTEIN; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; HOTAIR LONG UNTRANSLATED RNA, HUMAN; MIRN331 MICRORNA, HUMAN; TUMOR MARKER;

APOPTOSIS; ARTICLE; CANCER SIZE; CANCER STAGING; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GASTRIC CANCER CELL LINE; GROWTH DISORDER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN RNA BINDING; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STOMACH CANCER; STOMACH CARCINOMA; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; CANCER TRANSPLANTATION; CARCINOMA; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE METASTASIS; METABOLISM; MOLECULAR GENETICS; MORTALITY; MOUSE; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; STOMACH TUMOR; SURVIVAL; TUMOR MICROENVIRONMENT;

ANIMALS; BASE SEQUENCE; CARCINOMA; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; MICE; MICE, NUDE; MICRORNAS; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; RECEPTOR, ERBB-2; RNA, LONG NONCODING; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84899984643     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-92     Document Type: Article

References (40)

1. Coburn NG. Lymph nodes and gastric cancer. J Surg Oncol 2009, 99:199-206. 10.1002/jso.21224, 19142901.
2. Shi Y, Zhou Y. The role of surgery in the treatment of gastric cancer. J Surg Oncol 2010, 101:687-692. 10.1002/jso.21455, 20512944.
3. Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev 2009, 23:1494-1504. 10.1101/gad.1800909, 3152381, 19571179.
4. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet 2009, 10:155-159. 10.1038/nrg2521, 19188922.
5. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell 2011, 146:353-358. 10.1016/j.cell.2011.07.014, 3235919, 21802130.
6. Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, Tramontano A, Bozzoni I. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 2011, 147:358-369. 10.1016/j.cell.2011.09.028, 3234495, 22000014.
7. Wang Y, Xu Z, Jiang J, Xu C, Kang J, Xiao L, Wu M, Xiong J, Guo X, Liu H. Endogenous miRNA sponge lincRNA-RoR regulates Oct4, nanog, and Sox2 in human embryonic stem cell self-renewal. Dev Cell 2013, 25:69-80. 10.1016/j.devcel.2013.03.002, 23541921.
8. Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, Chen N, Sun F, Fan Q. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res 2010, 38:5366-5383. 10.1093/nar/gkq285, 2938198, 20423907.
9. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E, Chang HY. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007, 129:1311-1323. 10.1016/j.cell.2007.05.022, 2084369, 17604720.
10. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B, Li R, West RB, van de Vijver MJ, Sukumar S, Chang HY. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010, 464:1071-1076. 10.1038/nature08975, 3049919, 20393566.
11. Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T, Tanaka F, Shibata K, Suzuki A, Komune S, Miyano S, Mori M. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res 2011, 71:6320-6326. 10.1158/0008-5472.CAN-11-1021, 21862635.
12. Geng YJ, Xie SL, Li Q, Ma J, Wang GY. Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression. J Int Med Res 2011, 39:2119-2128. 10.1177/147323001103900608, 22289527.
13. Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R, Kim S, Safe S. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene 2013, 32:1616-1625. 10.1038/onc.2012.193, 3484248, 22614017.
14. Niinuma T, Suzuki H, Nojima M, Nosho K, Yamamoto H, Takamaru H, Yamamoto E, Maruyama R, Nobuoka T, Miyazaki Y, Nishida T, Bamba T, Kanda T, Ajioka Y, Taguchi T, Okahara S, Takahashi H, Nishida Y, Hosokawa M, Hasegawa T, Tokino T, Hirata K, Imai K, Toyota M, Shinomura Y. Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Cancer Res 2012, 72:1126-1136. 10.1158/0008-5472.CAN-11-1803, 22258453.
15. Endo H, Shiroki T, Nakagawa T, Yokoyama M, Tamai K, Yamanami H, Fujiya T, Sato I, Yamaguchi K, Tanaka N, Iijima K, Shimosegawa T, Sugamura K, Satoh K. Enhanced expression of long non-coding RNA HOTAIR is associated with the development of gastric cancer. PLoS One 2013, 8:e77070. 10.1371/journal.pone.0077070, 3795022, 24130837.
16. Hajjari M, Behmanesh M, Sadeghizadeh M, Zeinoddini M. Up-regulation of HOTAIR long non-coding RNA in human gastric adenocarcinoma tissues. Med Oncol 2013, 30:670.
17. Izaurralde E. Elucidating the temporal order of silencing. EMBO Rep 2012, 13:662-663. 10.1038/embor.2012.91, 3410391, 22722480.
18. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat Rev Genet 2008, 9:102-114.
19. Lee HE, Park KU, Yoo SB, Nam SK, Park DJ, Kim HH, Lee HS. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer 2013, 49:1448-1457. 10.1016/j.ejca.2012.10.018, 23146959.
20. Amaral PP, Neyt C, Wilkins SJ, Askarian-Amiri ME, Sunkin SM, Perkins AC, Mattick JS. Complex architecture and regulated expression of the Sox2ot locus during vertebrate development. RNA 2009, 15:2013-2027. 10.1261/rna.1705309, 2764477, 19767420.
21. Ravasi T, Suzuki H, Pang KC, Katayama S, Furuno M, Okunishi R, Fukuda S, Ru K, Frith MC, Gongora MM, Grimmond SM, Hume DA, Hayashizaki Y, Mattick JS. Experimental validation of the regulated expression of large numbers of non-coding RNAs from the mouse genome. Genome Res 2006, 16:11-19. 1356124, 16344565.
22. Fu X, Ravindranath L, Tran N, Petrovics G, Srivastava S. Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell Biol 2006, 25:135-141. 10.1089/dna.2006.25.135, 16569192.
23. Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, Xiong Y. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene 2011, 30:1956-1962. 10.1038/onc.2010.568, 3230933, 21151178.
24. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea MD, Thomas K, Presser A, Bernstein BE, van Oudenaarden A, Regev A, Lander ES, Rinn JL. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A 2009, 106:11667-11672. 10.1073/pnas.0904715106, 2704857, 19571010.
25. Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol 2012, 9:703-719. 10.4161/rna.20481, 3495743, 22664915.
26. Yoon JH, Abdelmohsen K, Kim J, Yang X, Martindale JL, Tominaga-Yamanaka K, White EJ, Orjalo AV, Rinn JL, Kreft SG, Wilson GM, Gorospe M. Scaffold function of long non-coding RNA HOTAIR in protein ubiquitination. Nat Commun 2013, 4:2939.
27. Huang TH, Morrison SL. A trimeric anti-HER2/neu ScFv and tumor necrosis factor-alpha fusion protein induces HER2/neu signaling and facilitates repair of injured epithelia. J Pharmacol Exp Ther 2006, 316:983-991.
28. Lemoine NR, Jain S, Silvestre F, Lopes C, Hughes CM, McLelland E, Gullick WJ, Filipe MI. Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Br J Cancer 1991, 64:79-83. 10.1038/bjc.1991.243, 1977330, 1677259.
29. Faltus T, Yuan J, Zimmer B, Kramer A, Loibl S, Kaufmann M, Strebhardt K. Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia 2004, 6:786-795. 10.1593/neo.04313, 1531682, 15720805.
30. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008, 19:1523-1529. 10.1093/annonc/mdn169, 18441328.
31. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182. 10.1126/science.3798106, 3798106.
32. Madarnas Y, Trudeau M, Franek JA, McCready D, Pritchard KI, Messersmith H. Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. Cancer Treat Rev 2008, 34:539-557. 10.1016/j.ctrv.2008.03.013, 18502589.
33. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726. 10.1200/JCO.20.3.719, 11821453.
34. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005, 16:273-278. 10.1093/annonc/mdi064, 15668283.
35. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007, 59:795-805. 10.1007/s00280-006-0337-z, 17031648.
36. Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N, Kitano S. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol 2005, 27:681-685.
37. Kameda T, Yasui W, Yoshida K, Tsujino T, Nakayama H, Ito M, Ito H, Tahara E. Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. Cancer Res 1990, 50:8002-8009.
38. Fang C, Zhao Y, Guo B. MiR-199b-5p targets HER2 in breast cancer cells. J Cell Biochem 2013, 114:1457-1463. 10.1002/jcb.24487, 23296799.
39. Epis MR, Barker A, Giles KM, Beveridge DJ, Leedman PJ. The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells. J Biol Chem 2011, 286:41442-41454. 10.1074/jbc.M111.301481, 3308856, 21971048.
40. Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, Ochiai A, Ruschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008, 52:797-805. 10.1111/j.1365-2559.2008.03028.x, 18422971.